A recent Dermatology digest,
as sent to subscribers

Study Type: Retrospective multicentre cohort study (18 Italian centres; n=98).

Key Question: Does achieving an overall response lasting ≥4 months (ORR4) on mogamulizumab predict survival and treatment-durability outcomes in real-world MF/SS?

Key Findings:

• ORR4 was achieved in 47.3% (44/93 evaluable), ranging from 10.0% in stage IIB to 70.8% in stage IVA1 (p=0.022).
• ORR4 was associated with better 24-month OS (76% vs 60%), PFS (58% vs 35%) and TTNT (76% vs 47%) on landmark analysis, confirmed in time-varying Cox models.
• Lack of ORR4 independently predicted worse OS (HR 3.18), PFS (HR 2.67) and earlier next-line therapy (HR 4.27). Skin adverse events were associated with higher ORR4 (70% vs 40%) but not independently with survival.

Clinical Relevance: ORR4 offers a practical on-treatment checkpoint for reviewing mogamulizumab benefit and planning next-line therapy or transplant in NHS cutaneous lymphoma MDTs.

Limitations: Retrospective design with a short 4-month landmark risks residual confounding and time-related bias, and ORR4 was not evaluable in 5 patients.

Study Type: Population-based matched cohort study (CPRD linked to hospital, mortality, deprivation and ethnicity data)

Key Question: What are the incidence, prevalence, mortality risk and life expectancy of patients with GPP in England, and do these vary by ethnicity and sex?

Key Findings:

• Among 25.8 million people (2008–2022), 991 had GPP (63% female; 10% Asian). Prevalence rose from 20.9 to 32.5 per million, and incidence reached 4.9 per million person-years after 2016. Onset was earlier in Asian than White patients (overall mean age 51.4 years).
• All-cause mortality was over three times higher than in matched comparators (aHR 3.19; 95% CI 2.58–3.91). Cause-specific risks were elevated for neoplasms, respiratory, digestive and circulatory disease, with the highest for sepsis (aHR 9.76; 4.92–19.35).
• Younger age at diagnosis was associated with the greatest loss of life expectancy.

Clinical Relevance: These data quantify GPP's burden and excess mortality in the English population, supporting prompt specialist referral, vigilance for sepsis and comorbidity, and service planning for targeted therapy access in the NHS.

Limitations: GPP was identified from coded primary care and hospital records without validation against clinical criteria, so misclassification (including confusion with palmoplantar pustulosis or pustular flares of plaque psoriasis) is likely.

Study Type: Narrative review (no systematic search methodology or quantitative synthesis described in the abstract).

Key Question: What factors, beyond labelled SPF, determine how effective sunscreen is in real-world use?

Key Findings:

• Real-world protection depends on interacting factors: wavelength coverage (UVB, UVA, and in selected contexts visible light), formulation, durability, regulatory standards and user behaviour, not SPF alone.
• SPF has recognised limitations as a sole efficacy marker, and efficacious products may under-perform in practice because of how people apply and use them.
• Evidence on systemic absorption, environmental impact and misinformation is appraised; the abstract gives no specific effect sizes or conclusions on these.

Clinical Relevance: Supports moving from uniform sunscreen advice to risk-stratified, behaviour-informed counselling, which is pertinent to UK patients with photosensitivity, skin cancer risk or skin of colour.

Limitations: As a narrative review, it likely carries selection bias, and the abstract reports no quantitative data or search methods.

Study Type: Phase III, multicentre, 4-part study (Part 2 randomised vs ustekinumab; Parts 1, 3, 4 open-label, 52 weeks).

Key Question: Is risankizumab effective and safe through 52 weeks in paediatric patients with moderate-to-severe psoriasis?

Key Findings:

• At week 16 (Part 2; risankizumab n=54, ustekinumab n=28), response rates were similar: sPGA 0/1 79.6% vs 75.0%; PASI90 64.8% vs 60.7%. PASI100 was numerically higher with risankizumab (40.7% vs 17.9%).
• In open-label Part 4 (n=30), week 16 PASI90 was 76.7% and PASI100 43.3%; responses were maintained or improved at week 52.
• Itch and quality of life improved at weeks 16 and 52 (Part 2 only). Safety was consistent with adult data.

Clinical Relevance: Risankizumab may offer an additional IL-23 option for children with moderate-to-severe psoriasis, though NHS availability will depend on licensing and NICE appraisal.

Limitations: Small samples and no reported statistical comparison with ustekinumab in the abstract, so apparent differences (e.g., PASI100) cannot be considered confirmed.

Study Type: Open-label, assessor-blinded single-arm feasibility study with historic placebo comparison (single UK centre, n=20 treated).

Key Question: Is a future RCT of JAK inhibition in moderate-to-severe palmoplantar pustulosis (PPP) feasible, and is there a preliminary efficacy signal for upadacitinib?

Key Findings:

• All feasibility criteria met: 28/67 (41.8%) consented, 19/20 (95%) achieved ≥80% adherence, 18/19 (94.7%) found treatment acceptable.
• Mean PP-PASI fell from 20.3 to 4.6 at week 8 (upadacitinib 30 mg, or 15 mg if higher risk); baseline-adjusted difference versus historic placebo was −12.3 (95% CI −15.8 to −8.9). PP-PASI75: 65% vs 3.2%.
• Common adverse events were headache, acne, and upper respiratory tract infection.

Clinical Relevance: PPP has limited effective licensed options in the UK, so this signal supports an upcoming multicentre active-comparator RCT; off-label use remains unsupported by controlled evidence.

Limitations: Efficacy estimates come from an uncontrolled, open-label, single-centre design compared against historic placebo data, so are highly susceptible to bias and confounding.

Study Type: Narrative review (written using AI methodology; no systematic search or quality appraisal described in the abstract).

Key Question: What is the current clinical and molecular understanding of scalp-ear-nipple (SEN) syndrome, and what remains unresolved?

Key Findings:

• SEN syndrome is caused by heterozygous *KCTD1* variants clustering in residues 20–74 (BTB/pre-BTB domains), consistent with a dominant-negative mechanism: mutant protein cannot bind AP-2α and poisons wildtype function via nonfunctional heteropentamers.
• Mouse conditional knockout data indicate that aplasia cutis congenita (ACC) arises from neural crest dysfunction rather than a primary keratinocyte defect, classifying it as a neurocristopathy.
• The only paper reporting direct KCTD1–β-catenin binding was retracted (2022); KCTD1 may also modulate Hedgehog, Notch and cAMP signalling, but relevance to SEN is unclear.

Clinical Relevance: For UK clinicians managing ACC or ectodermal dysplasia, this clarifies the molecular basis for genetic testing and counselling, though no formal clinical guidelines exist (about 30–50 confirmed cases worldwide).

Limitations: Review methodology is not described, and its reliance on AI-assisted writing raises unquantified concerns about accuracy and selection of evidence; no new clinical data are presented.

Study Type: Three-round Delphi expert consensus study (US board-certified dermatologists); not a systematic review or RCT.

Key Question: What are expert-agreed best practices for diagnosing and managing pseudofolliculitis barbae (PFB)?

Key Findings:

• 40 statements reached consensus (≥75% agreement), covering diagnosis, medical and procedural management, and occupational considerations.
• Consensus supported behavioural modification of hair removal as first-line therapy, targeted topical and systemic treatments, and procedural options including laser hair removal.
• No consensus on a standardised grading scale, oral isotretinoin for refractory disease, superficial chemical peels, or multiblade razors.

Clinical Relevance: PFB disproportionately affects patients with tightly curled hair, and these recommendations offer a structured framework for service-level pathways, though UK access to laser hair removal on the NHS and occupational advice (e.g. grooming policies) will need local adaptation.

Limitations: Panel composition was US-only and the abstract does not report panel size or the evidence base underpinning statements, limiting generalisability to UK practice.

Study Type: Qualitative study (semistructured interviews, thematic analysis), single-city US setting.

Key Question: How do transfeminine and nonbinary adults assigned male at birth experience hirsutism and access to hair removal?

Key Findings:

• Of 18 participants (17 transgender women, 1 nonbinary; age range 22–68), 14 self-rated clinically significant hirsutism, yet only 1 had a clinician diagnosis.
• Themes: experienced discrimination and rejection, anticipatory avoidance of social and romantic contact, interference with feminine gender expression, worsened gender dysphoria, and extensive daily concealment behaviours.
• Reported barriers to permanent hair removal: appointment burden, negative clinician attitudes, lack of transgender-inclusive services, cost, and no insurance coverage.

Clinical Relevance: Hair removal is a clinically meaningful gender-affirming intervention; UK clinicians should recognise unmet need and variable NHS access when advising and referring transfeminine patients.

Limitations: Small, single-city US sample with self-reported hirsutism, so findings may not transfer to the UK, where funding and service structures differ.